OCEAN BIOMEDICAL INC (OCEA) Stock Price, Forecast & Analysis
USA - NASDAQ:OCEA - US67644C1045 - Common Stock
OCEA Key Statistics, Chart & Performance
The current stock price of OCEA is 0.0205 USD. In the past month the price decreased by -63.91%. In the past year, price decreased by -98.47%.
OCEA Latest News, Press Relases and Analysis
OCEA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About OCEA
Company Profile
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
Company Info
OCEAN BIOMEDICAL INC
515 Madison Ave Suite 8078
New York City NEW YORK US
Employees: 9
Phone: 16469082658
OCEAN BIOMEDICAL INC / OCEA FAQ
Can you describe the business of OCEAN BIOMEDICAL INC?
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
Can you provide the latest stock price for OCEAN BIOMEDICAL INC?
The current stock price of OCEA is 0.0205 USD. The price decreased by -46.75% in the last trading session.
What is the dividend status of OCEAN BIOMEDICAL INC?
OCEA does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCEA stock?
OCEA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is OCEA stock listed?
OCEA stock is listed on the Nasdaq exchange.
What is the outstanding short interest for OCEAN BIOMEDICAL INC?
The outstanding short interest for OCEAN BIOMEDICAL INC (OCEA) is 0.05% of its float.
OCEA Technical Analysis
OCEA Financial Highlights
Over the last trailing twelve months OCEA reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 90.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1051% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |